Australia markets close in 4 hours 40 minutes

Imugene Limited (IMU.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.0570-0.0020 (-3.39%)
As of 11:12AM AEST. Market open.

Imugene Limited

4-6 Bligh Street
Suite 12.01, Level 12
Sydney, NSW 2000
Australia
61 2 9423 0881
https://www.imugene.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees

Key executives

NameTitlePayExercisedYear born
Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICDExecutive Chairman316.1kN/A1956
Ms. Leslie ChongCEO, MD & Executive Director1.05MN/AN/A
Dr. Nicholas J. Ede B.Sc.(Hons.), Ph.D.Head of Corporate Development489.47kN/AN/A
Dr. Monil Shah M.B.A., Pharm.D.Chief Business Officer799.2kN/AN/A
Dr. Bradley Glover Ph.D.Chief Operating OfficerN/AN/A1969
Ms. Ursula McCurrySenior Vice President of Clinical OperationsN/AN/AN/A
Dr. John ByonSenior Vice President of Clinical DevelopmentN/AN/AN/A
Dr. Joseph Paul Woodard Jr., M.D.Chief Medical OfficerN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.

Description

Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in phase 2 for gastric cancer; VAXINIA is in phase 1 MAST trial for patients with metastatic or advanced solid tumours; and CHECKvacc oncolytic virotherapy is in phase 1 clinical trial against metastatic triple negative breast cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling and is in phase I trial; CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus; and CF33 CD19 chimeric antigen receptor T cells therapies to target solid tumours. The company has a collaboration with Arovella Therapeutics Ltd to test the integration of Arovella's CAR19- iNKT cell therapy with the onCARlytics platform; and a license agreement with Precision Biosciences Inc. to acquire azer-cell allogeneic CD19 CAR Tcell therapy program. Imugene Limited is based in Sydney, Australia.

Corporate governance

Imugene Limited’s ISS governance QualityScore as of 1 June 2024 is 10. The pillar scores are Audit: 9; Board: 8; Shareholder rights: 1; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.